A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Crizotinib (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 01 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 01 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
- 10 Jun 2017 Biomarkers information updated